About RemeGen Co., Ltd.
RemeGen Co., Ltd. is a Chinese biopharmaceutical company founded in 2008 in Yantai, Shandong province, dedicated to the discovery, development and commercialisation of innovative biological medicines. The company is listed on the Shanghai STAR Market and on the Hong Kong Stock Exchange, and keeps its headquarters in Yantai with R&D centres in Beijing, Shanghai and California.
Its flagship products are two world-class biological drugs: telitacicept, a BLyS/APRIL fusion protein approved in China for systemic lupus erythematosus and developed for rheumatoid arthritis, myasthenia gravis and other autoimmune diseases; and disitamab vedotin, a HER2-targeting antibody-drug conjugate approved for gastric and urothelial cancer. They are joined by a development pipeline in oncology, ophthalmology and nephrology, including the ophthalmic candidate RC28-E.
RemeGen integrates proprietary protein expression, antibody engineering and conjugation platforms, together with large-scale biological manufacturing capacity in Yantai. For international partners, it is a Chinese originator biopharmaceutical company with global licensing and clinical trials under way for its lead molecules.
Its flagship products are two world-class biological drugs: telitacicept, a BLyS/APRIL fusion protein approved in China for systemic lupus erythematosus and developed for rheumatoid arthritis, myasthenia gravis and other autoimmune diseases; and disitamab vedotin, a HER2-targeting antibody-drug conjugate approved for gastric and urothelial cancer. They are joined by a development pipeline in oncology, ophthalmology and nephrology, including the ophthalmic candidate RC28-E.
RemeGen integrates proprietary protein expression, antibody engineering and conjugation platforms, together with large-scale biological manufacturing capacity in Yantai. For international partners, it is a Chinese originator biopharmaceutical company with global licensing and clinical trials under way for its lead molecules.